Finally, considering hRNase5/ANG as a predictive biomarker in pancreatic cancer, a subset of patients with hRNase5/ANGhigh-EGFR+ population (around 30% based on plasma hRNase5/ANG estimation [46]) may benefit from erlotinib treatment. Here, ANG is linked to pancreatic neoplasm.